Epigenomics Ownership
| EPGNF Stock | USD 0.79 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Epigenomics |
Epigenomics Pink Sheet Ownership Analysis
About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.39. Some equities with similar Price to Book (P/B) outperform the market in the long run. Epigenomics AG recorded a loss per share of 0.3. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 27th of December 2022. Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.The quote for Epigenomics AG is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Epigenomics AG call Gregory Hamilton at 49 30 243 450 or check out https://www.epigenomics.com.Currently Active Assets on Macroaxis
Other Information on Investing in Epigenomics Pink Sheet
Epigenomics financial ratios help investors to determine whether Epigenomics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Epigenomics with respect to the benefits of owning Epigenomics security.